Abstract
Epigenetic clocks have been widely evaluated as cancer biomarkers, but findings have been inconsistent across tumor types and clinical endpoints. This inconsistency may reflect a fundamental misspecification: standard clock analyses treat clock CpGs as scalar aging readouts, assuming that tumors shift along the same methylation-aging axis as normal tissue. We tested this assumption across nine TCGA (The Cancer Genome Atlas) cancer types using Horvath clock CpGs. Tumors did not show a consistent mean shift in Horvath age acceleration relative to normal tissue. Instead, they showed an order-of-magnitude increase in age-acceleration variance. Scalar clock summaries also failed as survival biomarkers, producing zero nominal associations after adjustment for age, sex, and stage. We therefore analyzed Horvath clock CpGs as a coordinated methylation system. PCA-derived tumor methylation programs captured 34.9%-50.8% of clock-CpG variance across cancers, and this structure persisted after adjustment for tumor purity, proliferative history, and global methylation instability. This indicates that tumor-associated clock-CpG variation is not random methylation disorder, but is organized along major axes of covariation. In fully adjusted Cox models, tumor methylation programs produced 15 nominal survival associations, four of which remained significant after FDR correction. Survival-associated programs were linked to transcriptional pathway activity, including UPR, EMT, IFN-γ response, and stemness, in directions consistent with their survival effects. These programs also persisted after controlling for tumor-normal differentially methylated regions, indicating that they were not explained by average cancer-associated methylation shifts. External validation in GSE72308 showed that two of three TCGA-nominated BRCA survival associations reproduced in the same protective direction. The dominance of tumor methylation programs over scalar clock summaries shows that the cancer-relevant signal in epigenetic clock CpGs is not methylation age, but coordinated tumor-state structure. In tumors, Horvath's clock CpGs are reorganized into methylation programs that capture survival-relevant and transcriptionally linked cancer biology.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study ONLY used openly available and de-identified human data from The Cancer Genome Atlas (TCGA) project. Clinical information was downloaded from the Genomic Data Commons (GDC) Data Portal (https://portal.gdc.cancer.gov/), and methylation data was retrieved from the UCSC Xena database (https://xenabrowser.net/datapages/) for 9 cancer types, as detailed in the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
TCGA methylation data are available online at the UCSC Xena browser. TCGA patient clinical data are available online at the GDC Data Portal. The validation breast cancer cohort (GSE72308) data are available online on the Gene Expression Omnibus repository. All data produced in the present study are contained in the manuscript.
https://portal.gdc.cancer.gov/





